Odyssey Therapeutics has priced its upsized initial public offering at $18 per share for 15.5 million shares, for gross proceeds of about $304 million, the company said late Thursday.
Underwriters have a 30-day option to purchase up to an additional 2.3 million shares.
The shares are expected to begin trading on Nasdaq on Friday, under the ticker, "ODTX."
The IPO expected to close on Monday, it added.